GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response

NCT04387201 on ClinicalTrials.gov · last registry update 2024-12-05

A small phase 4 — 23 participants, against a typical 75. The sponsor logged completion for 6 October 2023. Primary outcome, as filed: Cytokine Interleukin-6 (IL-6) Messenger Ribonucleic Acid (mRNA) Level (From Adipose Tissue). dulaglutide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: dulaglutide
Trulicity
Sponsor: The University of Texas Health Science Center, Houston
Sponsor type: Other
Enrollment: 23
Started: 2020-05-15
Primary completion: 2023-10-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Cytokine Interleukin-6 (IL-6) Messenger Ribonucleic Acid (mRNA) Level (From Adipose Tissue)

Conditions studied

Glucose Intolerance · Overweight and Obesity · Drug Effect · Adiposity

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.